Reduced monocytic IL10 expression in PD1 inhibitor-treated patients is a harbinger of severe immune-related adverse events

IF 7.1 1区 医学 Q1 ONCOLOGY European Journal of Cancer Pub Date : 2025-02-25 Epub Date: 2025-01-17 DOI:10.1016/j.ejca.2025.115252
Stanislav Rosnev , Baldur Sterner , Phillip Schiele , Stefan Kolling , Markus Martin , Anne Flörcken , Barbara Erber , Friedrich Wittenbecher , Grzegorz Kofla , Annika Kurreck , Tonio Johannes Lukas Lang , Jobst C. von Einem , Maria de Santis , Uwe Pelzer , Sebastian Stintzing , Lars Bullinger , Konrad Klinghammer , Dominik Geisel , Sebastian Ochsenreither , Marco Frentsch , Il-Kang Na
{"title":"Reduced monocytic IL10 expression in PD1 inhibitor-treated patients is a harbinger of severe immune-related adverse events","authors":"Stanislav Rosnev ,&nbsp;Baldur Sterner ,&nbsp;Phillip Schiele ,&nbsp;Stefan Kolling ,&nbsp;Markus Martin ,&nbsp;Anne Flörcken ,&nbsp;Barbara Erber ,&nbsp;Friedrich Wittenbecher ,&nbsp;Grzegorz Kofla ,&nbsp;Annika Kurreck ,&nbsp;Tonio Johannes Lukas Lang ,&nbsp;Jobst C. von Einem ,&nbsp;Maria de Santis ,&nbsp;Uwe Pelzer ,&nbsp;Sebastian Stintzing ,&nbsp;Lars Bullinger ,&nbsp;Konrad Klinghammer ,&nbsp;Dominik Geisel ,&nbsp;Sebastian Ochsenreither ,&nbsp;Marco Frentsch ,&nbsp;Il-Kang Na","doi":"10.1016/j.ejca.2025.115252","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Despite remarkable clinical efficacy, little is known about the system-wide immunological alterations provoked by PD1 blockade. Dynamics of quantitative immune composition and functional repertoire during PD1 blockade could delineate cohort-specific patterns of treatment response and therapy-induced toxicity.</div></div><div><h3>Methods</h3><div>We longitudinally assessed therapy-induced effects on the immune system in fresh whole blood using flow cytometry-based cell quantifications, accompanied by analyses of effector properties of all major immune populations upon cell-type specific stimulations. 43 cancer patients undergoing PD1 blockade were recruited with assessments performed pre-treatment and before cycles 2/4/6, which resulted in the collection of more than 30,000 cytometric data values.</div></div><div><h3>Results</h3><div>We observed no intrinsic immune pattern correlating with clinical outcome before PD1 blockade initiation, but cohort-specific immune alterations emerged during therapy. The most striking evolving changes in therapy responders were an increase in activated T and NK cell subsets, which showed high IFNγ and TNFα expression upon ex vivo stimulation. Patients affected by severe immune-related adverse events (s-irAE) presented with an analogously increased number of activated CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells compared to patients with no/mild irAE, but lacked the functional divergences observed between responders versus non-responders. Instead, their monocytes showed discriminatory functional deficits with less IL10 production upon stimulation, which led to an abrogated inhibition of T cell proliferation in vitro and thus may account for the observed T cell expansion in patients with s-irAE.</div></div><div><h3>Conclusion</h3><div>Our holistic explorative approach allowed the delineation of clinically relevant cohorts by treatment-triggered immune changes, potentially enabling better patient stratification and further revealed new mechanistic insights into the pathogenesis of s-irAE.</div></div>","PeriodicalId":11980,"journal":{"name":"European Journal of Cancer","volume":"217 ","pages":"Article 115252"},"PeriodicalIF":7.1000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0959804925000334","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/17 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Despite remarkable clinical efficacy, little is known about the system-wide immunological alterations provoked by PD1 blockade. Dynamics of quantitative immune composition and functional repertoire during PD1 blockade could delineate cohort-specific patterns of treatment response and therapy-induced toxicity.

Methods

We longitudinally assessed therapy-induced effects on the immune system in fresh whole blood using flow cytometry-based cell quantifications, accompanied by analyses of effector properties of all major immune populations upon cell-type specific stimulations. 43 cancer patients undergoing PD1 blockade were recruited with assessments performed pre-treatment and before cycles 2/4/6, which resulted in the collection of more than 30,000 cytometric data values.

Results

We observed no intrinsic immune pattern correlating with clinical outcome before PD1 blockade initiation, but cohort-specific immune alterations emerged during therapy. The most striking evolving changes in therapy responders were an increase in activated T and NK cell subsets, which showed high IFNγ and TNFα expression upon ex vivo stimulation. Patients affected by severe immune-related adverse events (s-irAE) presented with an analogously increased number of activated CD4 + and CD8 + T cells compared to patients with no/mild irAE, but lacked the functional divergences observed between responders versus non-responders. Instead, their monocytes showed discriminatory functional deficits with less IL10 production upon stimulation, which led to an abrogated inhibition of T cell proliferation in vitro and thus may account for the observed T cell expansion in patients with s-irAE.

Conclusion

Our holistic explorative approach allowed the delineation of clinically relevant cohorts by treatment-triggered immune changes, potentially enabling better patient stratification and further revealed new mechanistic insights into the pathogenesis of s-irAE.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在PD1抑制剂治疗的患者中,单核细胞IL10表达降低是严重免疫相关不良事件的前兆。
背景:尽管临床疗效显著,但人们对PD1阻断引起的全系统免疫改变知之甚少。PD1阻断期间定量免疫组成和功能库的动态可以描述治疗反应和治疗诱导毒性的队列特异性模式。方法:我们使用基于流式细胞术的细胞定量技术,对新鲜全血中治疗诱导的免疫系统效应进行了纵向评估,同时分析了所有主要免疫群体在细胞类型特异性刺激下的效应特性。招募了43名接受PD1阻断的癌症患者,在治疗前和2/4/6周期之前进行评估,收集了超过30,000个细胞计数数据值。结果:在PD1阻断开始之前,我们没有观察到与临床结果相关的内在免疫模式,但在治疗期间出现了队列特异性免疫改变。治疗应答者中最显著的进化变化是活化T和NK细胞亚群的增加,它们在体外刺激下显示出高的IFNγ和TNFα表达。受严重免疫相关不良事件(s-irAE)影响的患者与无/轻度irAE患者相比,CD4 +和CD8 + T细胞的活化数量类似地增加,但缺乏在应答者和无应答者之间观察到的功能差异。相反,他们的单核细胞在刺激时表现出歧视性功能缺陷,IL10的产生较少,这导致体外T细胞增殖抑制被取消,因此可能解释了s-irAE患者中观察到的T细胞扩增。结论:我们的整体探索性方法可以通过治疗引发的免疫变化来描述临床相关队列,有可能实现更好的患者分层,并进一步揭示s-irAE发病机制的新见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
European Journal of Cancer
European Journal of Cancer 医学-肿瘤学
CiteScore
11.50
自引率
4.80%
发文量
953
审稿时长
23 days
期刊介绍: The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.
期刊最新文献
Toremifene in desmoid fibromatosis: Prospective phase 2 study of two dose levels Aflibercept and 5-FU vs. FOLFOX as 1st line treatment for older adults or frail elderly patients with metastatic colorectal cancer – The randomized phase 2 AIO / IKF ELDERLY trial (AIO-KRK-0117 / IKF 629) Liver and peritoneal metastases of unknown primary site: French Intergroup Clinical Practice guidelines for diagnosis, treatment, and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, SFP, SFR, ACHBT, SFRO, SNFCP, AFEF, RENAPE, NET-CAPI) Diagnostic and prognostic parameters for immune checkpoint inhibitor-related myocarditis: A meta-analysis Second-line liposomal irinotecan plus S-1 vs. liposomal irinotecan plus 5-fluorouracil in metastatic pancreatic cancer: The phase I/II randomized NAPAN trial
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1